Top recovery stocks on the FTSE 100
Since the UK government unveiled its roadmap for reopening the economy investor sentiment is beginning to improve, so IG has identified some of the top recovery stocks to watch as the market picks up.
Since the Covid-19 pandemic caused the FTSE 100 to fall 34%, the blue-chip index has started to show signs of a meaningful recovery, climbing 24% after hitting a low of 4993 points in March.
The FTSE 100 has benefitted from the UK government unveiling its roadmap for reopening the economy, which has lifted investor sentiment. With markets picking up, IG has picked out some key growth stocks that could see significant gains as the world slowly emerges from lockdown.
Diageo
The maker of brands like Guinness and Johnnie Walker has naturally struggled as pubs and restaurants shut their doors due to government-imposed lockdowns. But consumers thirst for alcohol has not diminished, with supermarket sales seeing a sharp increase as people stock up on essentials in lockdown.
Diageo has been impacted by the Covid-19 pandemic, with its stock down 6% year-to-date. However, the drinks maker continues to outperform the broader market, with the FTSE 100 down 18% over the same period.
As the global economy shows signs of emerging from lockdown, analysts at Barclays remain optimistic that Diageo will have a stronger recovery than most, with the bank reiterating its ‘overweight’ rating for the stock and setting a target price of £32.30 per share – implying a potential upside of 8.5%.
Diageo closed at £29.54 a share on Thursday.
Lloyds
The UK lender is looking cheap, with its share price finding support at 30p levels after losing 50% of its value amid the economic fallout from the coronavirus pandemic.
As expected, Lloyds delivered a disappointing set of first quarter (Q1) figures, with profits down 95% after the bank was forced to take a £1.4 billion charge to cover a surge in bad loans as a result of the Covid-19 crisis.
Despite this, Lloyds remains the top pick among analysts covering the UK banking sector, with Citi issuing a target price of 42p, implying a potential upside of 31%.
The rationale behind analysts assessment of Lloyds comes down to the bank’s relatively healthy balance sheet, well-discounted asset quality risks and its likelihood of emerging from the Covid-19 crisis in a far stronger position than its rivals.
AstraZeneca
The drug maker continues to steady gains this year, up 13% year-to-date, with stock climbing 4% on Thursday after it announced that it is trialling one of its diabetes medications as a potential treatment for coronavirus.
Earlier this week, AstraZeneca received $1.2 billion from the US health department to develop, produce and deliver AZD1222, a potential Covid-19 vaccine it is working on in partnership with the University of Oxford.
The drug maker has already finalised manufacturing agreement to produce 400 million doses of the vaccine. Securing a partnership of this nature not only puts some daylight between it and rival GlaxoSmithKline, but could help AstraZeneca grab a slice of a $60 billion a year vaccine market.
As such, analysts remain upbeat about the stock’s performance in 2020, with AstraZeneca boasting eight ‘buy’ recommendations, two ‘hold’ and one ‘sell’.
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Seize your opportunity
Deal on the world’s stock indices today.
- Trade on rising or falling markets
- Get one-point spreads on the FTSE 100
- Unrivalled 24-hour pricing
See opportunity on an index?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on an index?
Don’t miss your chance – upgrade to a live account to take advantage.
- Get spreads from one point on the FTSE 100
- Trade more 24-hour indices than any other provider
- Analyse and deal seamlessly on smart, fast charts
See opportunity on an index?
Don’t miss your chance. Log in to take your position.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
